Search results for "BRONCHODILATOR"

showing 10 items of 142 documents

Guideline on management of the acute asthma attack in children by Italian Society of Pediatrics

2018

Abstract Background Acute asthma attack is a frequent condition in children. It is one of the most common reasons for emergency department (ED) visit and hospitalization. Appropriate care is fundamental, considering both the high prevalence of asthma in children, and its life-threatening risks. Italian Society of Pediatrics recently issued a guideline on the management of acute asthma attack in children over age 2, in ambulatory and emergency department settings. Methods The Grading of Recommendations Assessment, Development, and Evaluation (GRADE) methodology was adopted. A literature search was performed using the Cochrane Library and Medline/PubMed databases, retrieving studies in Englis…

MaleAsthma; Asthma attack; Children; GuidelinesPediatricsReviewGuidelineCochrane LibraryIpratropium bromidePediatricsSeverity of Illness Index0302 clinical medicineAnti-Asthmatic AgentsChildChildrenSocieties MedicalPediatriclcsh:RJ1-570PrognosisBronchodilator AgentsEpinephrineTreatment OutcomeInhalationItalyChild PreschoolAmbulatoryAdministrationCombinationPractice Guidelines as TopicDrug Therapy CombinationFemaleHumanmedicine.drugmedicine.medical_specialtyAdolescentPrognosiAsthma attackMEDLINEGuidelinesRisk Assessment03 medical and health sciencesDrug Therapy030225 pediatricsMedicalAdministration InhalationmedicineAnti-Asthmatic AgentHumansAsthma; Asthma attack; Children; Guidelines; Administration Inhalation; Adolescent; Anti-Asthmatic Agents; Asthma; Bronchodilator Agents; Child; Child Preschool; Drug Therapy Combination; Female; Humans; Italy; Male; Pediatrics; Prognosis; Risk Assessment; Severity of Illness Index; Societies Medical; Treatment Outcome; Practice Guidelines as TopicPreschoolBronchodilator AgentAsthmabusiness.industrylcsh:PediatricsEmergency departmentGuidelinemedicine.diseaseAsthma030228 respiratory systemPediatrics Perinatology and Child HealthbusinessSocieties
researchProduct

Clinical comparability between the CFC and HFA budesonide pressurised metered-dose inhalers in paediatric patients with asthma: a randomised controll…

2006

To evaluate the efficacy and tolerability of a novel hydrofluoroalkane (HFA) pressurised metered dose inhaler (pMDI) formulation of budesonide (Pulmicort) versus the conventional chlorofluorocarbon (CFC) pMDI formulation in paediatric patients with asthma.This was a Phase III, multicentre, 12-week, double-blind, randomised, parallel-group study involving children (6-12 years of age) with mild to moderate asthma. Patients received either budesonide HFA pMDI or budesonide CFC pMDI 200 mug twice daily, with or without a spacer (NebuChamber/Nebunette). Primary efficacy endpoint: mean percentage change in forced expiratory volume in 1 second (FEV(1)) from baseline to week 12. Secondary efficacy …

MaleBudesonideVital capacityHydrocarbons FluorinatedPeak Expiratory Flow Ratelaw.inventionchemistry.chemical_compoundDouble-Blind MethodRandomized controlled triallawmedicineHumansMetered Dose InhalersBudesonideChildAsthmaChlorofluorocarbonbusiness.industryInhalerGeneral Medicinemedicine.diseaseMetered-dose inhalerAsthmaBronchodilator AgentsTreatment OutcomeAerosol PropellantschemistryTolerabilityAnesthesiaFemaleChlorofluorocarbonsbusinessmedicine.drugCurrent Medical Research and Opinion
researchProduct

Effects of long-acting bronchodilators in COPD patients according to COPD severity and ICS use

2013

SummaryBackgroundIndacaterol is a once-daily, long-acting β2-agonist bronchodilator that improves dyspnoea and health status in patients with moderate-to-severe COPD. While its bronchodilator effects have been shown to be maintained in different patient subgroups, effects on clinical outcomes in certain subgroups are not yet defined.MethodsPost-hoc analysis of pooled clinical study data to investigate efficacy and safety of indacaterol compared with placebo and other long-acting bronchodilators (formoterol, salmeterol, open-label tiotropium) in patient subgroups defined by COPD severity (GOLD stage II or III; n = 4082) and ICS use at baseline (no/yes; n = 4088). Efficacy outcomes were troug…

MaleCopd patientsVital CapacityQuinolonesSeverity of Illness IndexPulmonary Disease Chronic ObstructiveForced Expiratory VolumeFormoterol FumarateBronchodilatorFormoterolSalmeterolSalmeterol XinafoateRandomized Controlled Trials as TopicIndacaterolCOPDMiddle AgedBronchodilator AgentsTreatment OutcomeEthanolaminesAnesthesiaIndansDrug Therapy CombinationFemaleSalmeterolmedicine.drugAdultPulmonary and Respiratory Medicinemedicine.medical_specialtymedicine.drug_classScopolamine DerivativesPlaceboDrug Administration ScheduleInternal medicineAdministration InhalationmedicineHumansCOPDAlbuterolTiotropium BromideAdrenergic beta-2 Receptor AgonistsGlucocorticoidsAgedbusiness.industryTiotropiummedicine.diseaserespiratory tract diseasesDyspneaLong actingIndacaterolFormoterolbusinessRespiratory Medicine
researchProduct

EFFECTS OF CROMAKALIM (BRL-34915) IN TRACHEA ISOLATED FROM ACTIVELY SENSITIZED GUINEA-PIGS

1993

Abstract The effects of cromakalim were examined in tracheal strips isolated from normal (unsensitized) guinea-pigs and from animals actively sensitized to bovine serum albumin. Sensitized tracheae exhibited hyper-responsiveness to KCl, acetylcholine and histamine. In normal and sensitized tracheae, cromakalim (0·01–10 μm) produced a concentration-related suppression of spontaneous tone. The ability of cromakalim to relax tracheal strips was reduced when tone was raised by KCl (25 Mm), acetylcholine (0·1 Mm) or histamine (0·1 Mm) and lost against KCl (120 Mm)-induced spasm. Procaine (5 Mm) abolished the relaxant effect of cromakalim whilst tetraethylammonium (8 Mm) was without effect. These…

MaleCromakalimPotassium ChannelsGuinea PigsPharmaceutical SciencePharmacologyGuinea pigchemistry.chemical_compoundProcainemedicineAnimalsBenzopyransPyrrolesBovine serum albuminPharmacologyTetraethylammoniumbiologyChemistryMuscle SmoothSerum Albumin BovineAcetylcholineBronchodilator AgentsTracheaKineticsmedicine.anatomical_structureAnesthesiaMuscle Tonusbiology.proteinPotassiumFemaleImmunizationCromakalimAcetylcholineHistaminemedicine.drugRespiratory tractHistamine
researchProduct

Clinical and Biological Heterogeneity in Children with Moderate Asthma

2003

To evaluate the relationship between inflammatory markers and severity of asthma in children, the amount of interleukin-8 (IL-8) and granulocyte/macrophage colony-stimulating factor (GM-CSF) released by peripheral blood mononuclear cells, exhaled nitric oxide (FE NO) levels, p65 nuclear factor-kappaB subunit, and phosphorylated IkBalpha expression by peripheral blood mononuclear cells were assessed in six control subjects, 12 steroid-naives subjects with intermittent asthma, and 17 children with moderate asthma. To investigate their predictive value, biomarker levels were correlated with the number of exacerbations during a 18-month follow-up period. We found that GM-CSF release was higher …

MaleExacerbationAnti-Inflammatory AgentsCritical Care and Intensive Care MedicineSynaptotagminsMedicineChildSalmeterol XinafoateCalcium-Binding ProteinMembrane GlycoproteinsRespiratory diseaseNF-kappa Binflammatory markersBronchodilator AgentsAnti-Inflammatory AgentSynaptotagmin IBiomarker (medicine)FemaleMembrane GlycoproteinAndrostadienes; Anti-Inflammatory Agents; NF-kappa B; Leukocytes Mononuclear; Membrane Glycoproteins; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Synaptotagmins; Albuterol; Asthma; Child; Receptors Cell Surface; Nerve Tissue Proteins; Nitric Oxide; Synaptotagmin I; Calcium-Binding Proteins; Interleukin-8; Adolescent; Bronchodilator Agents; Male; Biological Markers; Femalemedicine.symptomHumanmedicine.drugPulmonary and Respiratory MedicineAdolescentNerve Tissue ProteinsReceptors Cell SurfaceInflammationNitric OxidePeripheral blood mononuclear cellFluticasone propionateHumansAlbuterolBronchodilator AgentAsthmaAndrostadienefluticasone propionatebusiness.industryCalcium-Binding ProteinsInterleukin-8Granulocyte-Macrophage Colony-Stimulating Factormedicine.diseaseSynaptotagminAsthmaAndrostadienesasthma; inflammatory markers; fluticasone propionateNerve Tissue ProteinBiological MarkerExhaled nitric oxideImmunologyLeukocytes MononuclearFluticasonebusinessBiomarkersAmerican Journal of Respiratory and Critical Care Medicine
researchProduct

Pharmacological activity of PF-904 in guinea pig in vivo, and on human bronchus and neutrophils in vitro.

1997

The effects of PF-904 (4-amino-1-ethyl-6-methylpyrazino[2,3-c][1,2,6]thiadiazine 2,2-dioxide), a pyrazinothiadiazine derivative, were examined in guinea-pig airways in vivo, in human isolated bronchus and human polymorphonuclear leukocytes. PF-904 (12.5-200 mg/kg, intraduodenal) reduced bronchoconstriction in response to histamine, arachidonic acid, platelet-activating factor (PAF) and methacholine. PF-904 (50-200 mg/kg) prevented PAF-induced airways hyperreactivity and inhibited antigen-induced bronchoconstriction, airway microvascular leakage and eosinophil lung accumulation, but antigen-induced airways hyperresponsiveness was not reduced. PF-904 (1 microM-1 mM) produced complete inhibiti…

MaleNeutrophilsPhosphodiesterase InhibitorsGuinea PigsBronchiPharmacologyIn Vitro TechniquesBronchial Provocation TestsCapillary Permeabilitychemistry.chemical_compoundIn vivoSuperoxidesmedicineAnimalsHumansAnti-Asthmatic AgentsPlatelet Activating FactorRolipramPharmacologyBronchusThiadiazinesAnti-Inflammatory Agents Non-SteroidalPhosphodiesteraseBiological activityrespiratory systemBronchodilator AgentsN-Formylmethionine Leucyl-Phenylalaninemedicine.anatomical_structurechemistryBiochemistryPyrazinesBronchoconstrictionMethacholinemedicine.symptomBronchial HyperreactivityHistaminemedicine.drugEuropean journal of pharmacology
researchProduct

The Role of Transforming Growth Factor-β1 in Airway Inflammation of Childhood Asthma

2013

TGF-beta-targeting structural and inflammatory cells has been implicated in the mechanisms leading to the inflammatory and restructuring processes in asthma, suggesting an impact of TGF-beta1 signaling on the development and persistency of this disease. We investigated the potential early involvement of TGF-beta1 activity in the immunological and molecular mechanisms underlying progression of inflammation in childhood asthma. We evaluated the levels of TGF-beta1 in induced sputum supernatants (ISSs) and the expression of small mother cell against decapentaplegic (Smad) 2 and Smad7 proteins in induced sputum cells (ISCs) from children with intermittent asthma (IA), moderate asthma (MA) and c…

MaleNeutrophilsSmad2 ProteinSMADEosinophilAdrenal Cortex HormoneSeverity of Illness IndexAdrenal Cortex HormonesImmunology and AllergyAge FactorPhosphorylationChildLungNeutrophilAge FactorsBronchodilator Agentsmedicine.anatomical_structureFemalemedicine.symptomCase-Control StudieHumanSignal TransductionGranulocyte activationAdolescentImmunologyAge Factors; Humans; Child; Macrophage-1 Antigen; Adrenal Cortex Hormones; Granulocytes; Neutrophils; Phosphorylation; Eosinophils; Adolescent; Signal Transduction; Male; Severity of Illness Index; Respiratory Mucosa; Asthma; Transforming Growth Factor beta1; Epithelial Cells; Lung; Smad2 Protein; Case-Control Studies; Smad7 Protein; Sputum; Administration Inhalation; Bronchodilator Agents; Cell Line; Female; Cell AdhesionMacrophage-1 AntigenCD18InflammationRespiratory MucosaGranulocyteCell LineSmad7 ProteinTransforming Growth Factor beta1Administration InhalationCell AdhesionmedicineHumansCell adhesionBronchodilator AgentPharmacologyEpithelial Cellbusiness.industrySputumGranulocyteEpithelial CellsEosinophilAsthmaEosinophilsCase-Control StudiesImmunologySputumbusinessGranulocytesInternational Journal of Immunopathology and Pharmacology
researchProduct

Age- and sex-dependent differences in patients with severe asthma included in the German Asthma Net cohort.

2020

Severe asthma affects less than 5% of asthmatics, but is associated with high costs and increased mortality. The aim of this study was to assess age- and sex-dependent differences in this patient group.Retrospective analysis of 1317 children and adults with severe asthma who are included in the German Asthma Net registry.There were more adults than children in the registry and patients' mean age was 52. Apart from children18 years, there were more women (57%) than men. The age of first diagnosis ranged from 0 to 76 years. 38% of patients had a positive bronchial reversibility after short acting bronchodilators. Quality of life, FEV1 and MEF 25 decreased with older age whereas treatment with…

MalePediatricsDiseaseOmalizumabSeverity of Illness IndexGermanCohort Studies0302 clinical medicineGermany030212 general & internal medicineAnti-Asthmatic AgentsChildAged 80 and overAge FactorsAntibodies MonoclonalMiddle AgedBronchodilator AgentsChild PreschoolCohortlanguageFemalePulmonary and Respiratory MedicineAdultmedicine.medical_specialtyAdolescentSevere asthmamacromolecular substancesAge and sex03 medical and health sciencesYoung AdultSex FactorsAge groupsmedicineHumansIn patientGlucocorticoidsAsthmaAgedMaximal Expiratory Flow RateRetrospective Studiesbusiness.industryInfantImmunoglobulin Emedicine.diseaselanguage.human_languageAsthmarespiratory tract diseases030228 respiratory systemQuality of LifebusinessRespiratory medicine
researchProduct

Effects of inhaled glaucine on pulmonary responses to antigen in sensitized guinea pigs.

2000

The alkaloid (S)-(+)-1,2,9,10-tetramethoxyaporphine (glaucine) is a phosphodiesterase 4 inhibitor with bronchodilator and anti-inflammatory activity in vitro. In this study, we examined the in vivo effects of glaucine on an animal model of asthma. In ovalbumin sensitized guinea pigs, inhaled glaucine (10 mg ml(-1), 3 min) inhibited the acute bronchoconstriction produced by aerosol antigen (antigen response was 256+/-42 and 95+/-14 cm H(2)O l(-1) s(-1) in control and glaucine-treated animals, respectively; P<0.05). Pretreatment with glaucine (10 mg ml(-1), 10 min inhalation, 30 min pre- and 3 h post-antigen exposure) markedly reduced airway hyperreactivity to histamine, eosinophil lung accum…

MalePulmonary CirculationAporphinesEosinophil Peroxidasemedicine.drug_classBronchoconstrictionGuinea PigsPharmacologyGuinea pigCapillary Permeabilitychemistry.chemical_compoundBronchodilatormedicineCyclic AMPAnimalsAntigensLungPharmacologybiologyInhalationDose-Response Relationship Drugbusiness.industryrespiratory systemEosinophilGlaucineCyclic Nucleotide Phosphodiesterases Type 4EosinophilsTracheamedicine.anatomical_structurechemistryPeroxidases3'5'-Cyclic-AMP PhosphodiesterasesImmunologybiology.proteinBronchoconstrictionVascular Resistancemedicine.symptomBronchial HyperreactivitybusinessEosinophil peroxidaseHistamineHistamineEuropean journal of pharmacology
researchProduct

Indacaterol vs tiotropium in COPD patients classified as GOLD A and B

2015

SummaryIntroductionAccording to current GOLD strategy, patients with COPD classified as groups A and B may be treated with inhaled bronchodilators, either long-acting β2-agonist (LABA) or long-acting muscarinic antagonist (LAMA). However, there is little guidance on which class of agent is preferred and a lack of prospective data to differentiate the two.MethodsIn this study, we performed post-hoc analyses of pooled data from two prospective, controlled clinical trials comparing the LABA indacaterol and LAMA tiotropium in 1422 patients with moderate airflow limitation and no history of exacerbations in the previous year. This population fits the definitions of GOLD A and B groups and could …

MalePulmonary and Respiratory MedicineEfficacyPopulationINDEXESQuinolonesOBSTRUCTIVE PULMONARY-DISEASEPulmonary Disease Chronic ObstructiveHumansMedicineCOPDCOHORTProspective StudiesGOLDTiotropium BromideeducationDYSPNEAIndacateroleducation.field_of_studyCOPDDose-Response Relationship Drugbiologybusiness.industryTiotropiumONCE-DAILY INDACATEROLMuscarinic antagonistForced Expiratory Flow RatesBaseline Dyspnea IndexMiddle AgedLamabiology.organism_classificationmedicine.diseaseBronchodilator Agentsrespiratory tract diseasesClinical trialTreatment OutcomeAnesthesiaIndansCohortIndacaterolFemalebusinessCLINICAL METHODSFollow-Up Studiesmedicine.drugRespiratory Medicine
researchProduct